Cargando…

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib

The use of 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) in subjects with advanced basal cell carcinoma (BCC) has not been fully explored due to the rarity of disease presentation. This study evaluated PET/CTs from subjects with advanced BCC participating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thacker, Curtis A, Weiss, Glen J, Tibes, Raoul, Blaydorn, Lisa, Downhour, Molly, White, Erica, Baldwin, Jason, Hoff, Daniel D, Korn, Ronald L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2012
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544445/ https://www.ncbi.nlm.nih.gov/pubmed/23342272 http://dx.doi.org/10.1002/cam4.33

Ejemplares similares

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
por: Weiss, Glen J., et al.
Publicado: (2011)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Yurchenko, Andrey A., et al.
Publicado: (2022)

Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
por: Su, Maxwell G., et al.
Publicado: (2020)

Treatment of Locally Advanced Basal Cell Carcinomas with Vismodegib
por: Mastronardi, Luis, et al.
Publicado: (2021)

Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib
por: Sternfeld, Amir, et al.
Publicado: (2020)

Gross Tumor Delineation in Esophageal Cancer on MRI Compared With (18)F-FDG-PET/CT
por: Vollenbrock, Sophie E., et al.
Publicado: (2019)

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
por: Odom, Dawn, et al.
Publicado: (2017)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
por: Batty, Nicolas, et al.
Publicado: (2012)

Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
por: Martins, Pedro Carvalho, et al.
Publicado: (2019)

Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds
por: Yang, Hyekyung, et al.
Publicado: (2015)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
por: Macha, Muzafar A, et al.
Publicado: (2013)

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Aditya, Suruchi, et al.
Publicado: (2013)

Rapid response to vismodegib in a patient with advanced basal cell carcinoma
por: Vornicova, Olga, et al.
Publicado: (2015)

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face
por: Block, Alec M., et al.
Publicado: (2015)

Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
por: Miedema, Jayson, et al.
Publicado: (2017)

Vismodegib and orbital excision for treating locally advanced basal cell carcinoma
por: Hogarty, Daniel T, et al.
Publicado: (2018)

Vismodegib treatment in advanced basal cell carcinomas: Real‐life experience
por: Villani, Alessia, et al.
Publicado: (2021)

Comparative study of (18)F-FDG-PET/CT imaging and serum hTERT mRNA quantification in cancer diagnosis
por: Ping, Bingqiong, et al.
Publicado: (2015)

Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical approach and genetic analysis
por: Sinx, Kelly A.E., et al.
Publicado: (2018)

Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
por: Gampala, Silpa, et al.
Publicado: (2021)

Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib
por: Orduz Robledo, Mariana, et al.
Publicado: (2018)

A Non-Interventional Study on Vismodegib for Basal Cell Carcinoma in Swedish Patients
por: Bendsöe, Niels, et al.
Publicado: (2023)

Utilizing (18)F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
por: Momcilovic, Milica, et al.
Publicado: (2018)

(18)F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
por: Korn, Ronald L., et al.
Publicado: (2017)

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma
por: Chang, Anne Lynn S., et al.
Publicado: (2016)

Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib
por: Swisher, Austin R, et al.
Publicado: (2022)

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
por: García Ruiz, Antonio J, et al.
Publicado: (2022)

Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion
por: Dodson, Joseph, et al.
Publicado: (2022)

Characterization of intractable diarrhea resulting from vismodegib treatment for basal cell nevus syndrome
por: Patel, Ashmi, et al.
Publicado: (2022)

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Bertrand, Nicolas, et al.
Publicado: (2021)

Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series
por: Jameson, Gayle S., et al.
Publicado: (2009)

18-FDG PET in lung transplantation
por: Algieri, I, et al.
Publicado: (2015)

Myocarditis on (18)FDG-PET imaging
por: Chaaban, Nourhan, et al.
Publicado: (2022)

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib
por: Yoon, Jaeyoung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jdlcra41ftpre6qs6co42occov